Cytek Biosciences (CTKB) Receivables (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Receivables data on file, last reported at $51.9 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 5.68% year-over-year to $51.9 million; the trailing twelve-month figure through Mar 2026 stood at $51.9 million (down 5.68% YoY), and the FY2025 full-year result was $62.5 million, up 3.17% from the prior year.
• Receivables for Q1 2026 stood at $51.9 million, down from $62.5 million in the prior quarter.
• Across five years, Receivables topped out at $62.5 million in Q4 2025 and bottomed at $32.0 million in Q1 2022.
• The 5-year median for Receivables is $51.9 million (2026), against an average of $50.1 million.
• The widest annual swing landed in 2022, when Receivables surged 64.19%; it then dropped 10.04% in 2024.
• A 5-year view of Receivables shows it stood at $48.9 million in 2022, then climbed by 14.46% to $55.9 million in 2023, then advanced by 8.33% to $60.6 million in 2024, then climbed by 3.17% to $62.5 million in 2025, then slipped by 16.97% to $51.9 million in 2026.
• The last three Receivables figures came in at $51.9 million (Q1 2026), $62.5 million (Q4 2025), and $56.6 million (Q3 2025), per Business Quant data.

Peer Comparison